DEFENCE THERAPEUTICS INC
Commented by Stefan Feulner on December 30th, 2022 | 17:52 CET
BioNTech, Defence Therapeutics, Pfizer - The cards are being reshuffled
The Corona pandemic is seemingly coming to an end after almost three long years. The return to normality, now in China and the rest of the world, is a relief for society and the economy. In contrast, vaccine manufacturers are losing a billion-dollar business that is difficult to compensate for with products in other areas of application. Nevertheless, the stock market valuations of the vaccine producers continue to be exorbitantly high, as does their drop in value.
Read
Commented by Fabian Lorenz on December 19th, 2022 | 13:57 CET
BioNTech top, Morphosys flop and Defence Therapeutics takeover candidate?
Biotech shares are volatile. Investors were reminded of this again just last week. Moderna shares initially rose by almost 30%, only to fall back by around 10% towards the weekend. But overall, the mood in the biotech segment was positive. Moderna reported positive study results on a combination therapy of a Moderna cancer vaccine and the tumor drug pembrolizumab from Merck & Co. At BioNTech, two buy recommendations and the expansion in Asia created a good mood. This mood has also prevailed at Defence Therapeutics for several weeks. The Canadians reported positive study results against tumors, and their Accum technology delivers what it promises, in which case mRNA specialists such as Moderna, BioNTech and Co. should be interested in a cooperation or even acquisition. In contrast, Morphosys slides to a new multi-year low.
Read
Commented by André Will-Laudien on December 5th, 2022 | 12:43 CET
Attention biotech stocks: Bayer, BioNTech, Defence Therapeutics and Morphosys - These stocks look good!
After months of selling off, they are back: biotech stocks! A strong turn on the NASDAQ quickly flushed the beaten-up stocks back to the top of the hit lists. With COVID out of the spotlight, companies are returning to their long-term research lines. These have been heavily focused on cancer in recent years, and now there is even groundbreaking news on metastasis. BioNTech has thus already gained more than 40% since the October low. Morphosys, on the other hand, lost another 40% after an Alzheimer's study failed to deliver valuable results. It is worth taking another look at the sector.
Read
Commented by Nico Popp on November 30th, 2022 | 13:33 CET
Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech
Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.
Read
Commented by Stefan Feulner on November 21st, 2022 | 11:07 CET
Morphosys, Defence Therapeutics, Evotec - Stabilization after the sell-off
After the publication of the figures for the third quarter, many biotech companies were able to surprise positively. Due to the partly panic-like sell-off in this capital-intensive sector, there are attractive entry opportunities at a strongly discounted level, which should pay off with disproportionate price gains in the long term. The fact that promising companies are already trading below their cash levels shows that the panic is exaggerated. There are currently signs of a bottoming out, which could herald the next upward wave.
Read
Commented by André Will-Laudien on November 16th, 2022 | 11:27 CET
That hit home! Roche and Morphosys fail with Alzheimer's study, Bayer and Defence Therapeutics continue to rise strongly
It is common for biotech stocks to publish study results as well as figures several times a year. Since there are usually only expenses and few sales to report for these stocks fundamentally, analysts focus on the clinical successes in the way of a trial for the approval of new active substances. This can sometimes lead to erratic price movements. Roche and Morphosys suffered the same fate at the beginning of the week, with their share prices plummeting on the back of bad news. We take a look at a hot sector.
Read
Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET
BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?
BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.
Read
Commented by Stefan Feulner on October 26th, 2022 | 10:15 CEST
BioNTech, Defence Therapeutics, MorphoSys - The rebound is on the way
The biotech sector is a growth market and, therefore, extremely capital-intensive. Due to the stricter monetary policy of the central banks, investors have given the promising sector the cold shoulder in recent months. Sector indices lost around 30% of their value, while the prices of individual stocks with a full development pipeline halved. The fact that several promising long-term companies are already trading below their cash levels shows that the panic is exaggerated. There are signs of a bottoming out, which could herald the next upward wave.
Read
Commented by Nico Popp on October 17th, 2022 | 12:21 CEST
Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?
After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.
Read
Commented by André Will-Laudien on October 13th, 2022 | 14:10 CEST
Attention, turnaround: Bayer, BioNTech, Defence Therapeutics, MorphoSys - These biotech stocks are way down!
Even though more people are being diagnosed with cancer today, and the disease remains the leading cause of death, the number of people dying from cancer is trending downward. In recent years, respectively, survival rates have been steadily increasing. The relative proportion of survivors based on all cancer types in the US has increased from 50% to more than 67% over the past two decades, so today, two out of three patients with a serious disease are still alive after five years. In Europe, too, there has been an increase in 5-year survival rates for the most common cancer types. This is encouraging and draws attention to the oncology sector. Which biotech stocks are significant here and offer a good entry point?
Read